Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice

Inflammation Research

Volumn 56, Issue 1, 2007, Pages 17-23

  Tanaka, K ^a   Urata, N ^a   Mikami, M ^a   Ogasawara, M ^b   Matsunaga, T ^b   Terashima, N ^a   Suzuki, H ^b  

^a TOYAMA CHEMICAL CO LTD   (Japan)

^b Toyama Prefectural Institute for Pharmaceutical Research   (Japan)

Author keywords

Anti rheumatic drug; Iguratimod; Inflammatory cachexia; Interleukin 6; Mouse model

Indexed keywords

ALBUMIN; ANTIRHEUMATIC AGENT; IGURATIMOD; INDOMETACIN; INTERLEUKIN 6; METHOTREXATE; PREDNISOLONE;

ADIPOSE TISSUE; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CANCER CACHEXIA; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFECT; EPIDIDYMIS FAT; GASTROCNEMIUS MUSCLE; GENE EXPRESSION REGULATION; MALE; MOUSE; MUSCLE ATROPHY; NONHUMAN; NUTRITIONAL STATUS; PROPHYLAXIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; WASTING SYNDROME;

ADENOCARCINOMA; ADIPOSE TISSUE; ANIMALS; ANTIRHEUMATIC AGENTS; BLOOD GLUCOSE; BODY WEIGHT; CACHEXIA; CHOLESTEROL; CHROMONES; COLONIC NEOPLASMS; EATING; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; NEOPLASM TRANSPLANTATION; ORGAN SIZE; RNA, MESSENGER; SULFONAMIDES;

EID: 33847635319     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-6022-9     Document Type: Article

References (29)

1. Espat NJ, Copeland EM, Moldawer LL. Tumor necrosis factor and cachexia: a current perspective. Surg Oncol 1994; 3: 255-62.
2. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-4.
3. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-86.
4. Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology (Oxford). 2004; 43: 1219-23.
5. Walsmith J, Abad L, Kehayias J, Roubenoff R. Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol 2004; 31: 23-9.
6. Fathalla B, Hamada K, Vannier E, Smith D, Edwards C 3rd, Roubenoff R. Effects of aging and cytokine blockade on inflammatory cachexia. Clin Exp Rheumatol 2004; 22: 85-90.
7. Paget J. Nervous mimicry of organic disease. Lancet 1873; ii: 727-9.
8. Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. Inhibitory effect on the production of interleukin-1 and interleukin-6. J Pharmacobio-Dyn 1992; 15: 649-55.
9. Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A et al. Inhibitory effect of a new anti-rheumatic drug T-614 in costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 1999; 133: 566-74.
10. Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 2001; 28: 2591-6.
11. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford). 2003; 42: 1365-71.
12. Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, Abe C. Pharmacological studies of T-614, a novel antiinflammatory agent. effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/l mice. Int J Immunother 1993; 9: 69-78.
13. Inaba T, Tanaka K, Takeno R, Nagaki H, Yoshida C, Takano S. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones; Anti-arthiritic effect of the formylamino compound (T-614) in chronic inflammatory disease models. Chem Pharm Bull 2000; 48: 131-9.
14. Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7- methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: anti-inflammatory, analgesic and other related properties. Arzneimittelforschung 1992; 42: 935-44.
15. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 1990; 50: 2290-5.
16. Soda K, Kawakami M, Kashii A, Miyata M. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 1995; 62: 332-6.
17. Yasumoto K, Mukaida N, Harada A, Kuno K, Akiyama M, Nakashima E et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res 1995; 55: 921-7.
18. Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia-inducing and-non-inducing clones of murine colon 26 carcinoma. Int J Cancer 1995; 61: 522-8.
19. Iizuka N, Hazama S, Yoshimura K, Yoshino S, Tangoku A, Miyamoto K et al. Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer 2002; 99: 286-91.
20. Yoshizawa K, Okamoto T, Moriya K, Izawa A, Satoh Y, Naruto M et al. Effects of natural human interleukin-6 on thrombopoiesis and tumor progression in tumor-bearing mice. Cancer Lett 1994; 79: 83-9.
21. Strassmann G, Jacob CO, Evans R, Beall D, Fong M. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 1992; 148: 3674-8.
22. Fujita J, Tsujinaka T, Yano M, Ebisui C, Saito H, Katsume A et al. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 1996; 68: 637-43.
23. Tracey D. Interleukin-1 as a therapeutic target. Annu Rep Med Chem 1994; 29: 205-14.
24. Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 2002; 51: 188-94.
25. Abe C. Immunotherapy on arthritis in experimantal animal models (in Japanese). Jpn J Inflammation 1992; 12: 417-22.
26. Segal R, Dayan M, Zinger H, Mozes E. Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation. Clin Exp Immunol 1995; 101: 66-72.
27. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol 2003; 30: 2193-200.
28. McCarthy DO, Whitney P, Hitt A, Al-Majid S. Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. Res Nurs Health 2004; 27: 174-84.
29. Hara M, Abe T, Yamaguchi T. Umetani I. The efficacy and safety study of T-614 (iguratimod), a newly developed DMARD, on patients with rheumatoid arthritis. Arthritis Rheum 2004; 50 (9 suppl): S180-1.